SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISON OF GLASDEGIB PLUS LOW DOSE ARA-C VERSUS A HYPOMETHYLATING AGENT FOR ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY

被引：0
|
作者：
Forsythe, A. [1 ]
Arondekar, B. [2 ]
Tremblay, G. [1 ]
Chan, G. [2 ]
Su, Y. [3 ]
机构：
[1] Purple Squirrel Econ, New York, NY USA
[2] Pfizer Inc, Collegeville, PA USA
[3] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.103
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN21
引用
收藏
页码：A415 / A415
页数：1
相关论文
共 50 条
  • [31] Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan
    Asada, Noboru
    Ando, Jun
    Takada, Satoru
    Yoshida, Chikashi
    Usuki, Kensuke
    Shinagawa, Atsushi
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Iida, Hiroatsu
    Dobashi, Nobuaki
    Okubo, Sumiko
    Honda, Hideyuki
    Soshin, Tomomi
    Nishimura, Yasuko
    Tsutsui, Atsuko
    Mukai, Harumi
    Yamamoto, Kazuhito
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (07) : 595 - 603
  • [32] IDARUBICIN PLUS INTERMEDIATE-DOSE ARA-C IN REFRACTORY AND RELAPSING ADULT ACUTE MYELOID-LEUKEMIA
    DELASERNA, FJ
    TOMAS, JF
    SOLANO, C
    DIAZMEDIAVILLA, J
    SANCHEZ, JJ
    GARCIADEPAREDES, ML
    BLOOD, 1994, 84 (10) : A304 - A304
  • [33] Curative chemotherapy for acute myeloid leukemia: The development of high-dose ara-C from the laboratory to bedside
    Capizzi, RL
    INVESTIGATIONAL NEW DRUGS, 1996, 14 (03) : 249 - 256
  • [34] DAE (DAUNORUBICIN, ARA-C, AND ETOPOSIDE) AND INTERMEDIATE DOSE ARA-C FOR REMISSION INDUCTION AND CONSOLIDATION TREATMENT OF ADULT PATIENTS WITH ACUTE MYELOID-LEUKEMIA
    HWANG, WL
    YOUNG, JH
    GAU, JP
    HU, HT
    TSAI, YT
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1992, 15 (06): : 531 - 534
  • [35] A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
    Cortes, Jorge E.
    Heidel, Florian H.
    Heuser, Michael
    Fiedler, Walter
    Smith, B. Douglas
    Robak, Tadeusz
    Fernandez, Pau Montesinos
    Ma, Weidong Wendy
    Shaik, M. Naveed
    Zeremski, Mirjana
    O'Connell, Ashleigh
    Chan, Geoffrey
    BLOOD, 2016, 128 (22)
  • [36] Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Laloi, Louise
    Billotey, Natacha Chaumard
    Dumas, Pierre-Yves
    Paul, Franciane
    Villate, Alban
    Simand, Celestine
    Fornecker, Luc
    Puisset, Florent
    Bertoli, Sarah
    Simonet, Marion Boissard
    Laribi, Kamel
    Houyou, Dyhia
    Santagostino, Alberto
    Michel, Claire
    Guepin, Gabrielle Roth
    Guerineau, Elodie
    Tabrizi, Reza
    Hunault, Mathilde
    Giltat, Aurelien
    Kaphan, Eleonore
    Bulabois, Claude
    Cartet, Elodie
    Rocher, Clement
    Lachenal, Florence
    Morisset, Stephane
    Recher, Christian
    Pigneux, Arnaud
    Belhabri, Amine
    Michallet, Mauricette
    Michallet, Anne-Sophie
    CANCER MEDICINE, 2023, 12 (06): : 7175 - 7181
  • [37] SUCCESSFUL TREATMENT WITH LOW-DOSE ARA-C IN DENOVO ACUTE MYELOID-LEUKEMIA WITH TRILINEAGE MYELODYSPLASIA
    KAWANO, F
    NISHIMURA, Y
    TSUKAMOTO, A
    SATOH, M
    SANADA, I
    SHIDO, T
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 1992, 55 (01) : 101 - 102
  • [38] Venetoclax plus Cladribine plus Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax plus Hypomethylating Agent
    Steinauer, Nickolas
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Saliba, Antoine
    Hefazi, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Pardanani, Animesh D.
    Badar, Talha
    Murthy, Hemant S.
    Foran, James M.
    Yi, Cecilia Y. Arana
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2023, 142
  • [39] The comparative effectiveness of glasdegib in combination with low-dose cytarabine versus azacitidine by bone marrow blasts counts among patients with newly-diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
    van Beekhuizen, Sophie
    Hu, Yannan
    Gezin, Ana
    Heeg, Bart
    Bell, Timothy
    Charaan, Majed
    Brown, Andrew
    Chan, Geoffrey
    Cappelleri, Joseph C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial
    Mussai, Francis
    De Santo, Carmela
    Cheng, Paul
    Thomas, Ian F.
    Ariti, Cono
    Upton, Laura
    Scarpa, Ugo
    Stavrou, Victoria
    Sydenham, Mia
    Burnett, Alan K.
    Knapper, Steven K.
    Mehta, Priyanka
    McMullin, Mary F.
    Copland, Mhairi
    Russell, Nigel H.
    Dennis, Mike
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (05) : 573 - 578
12345